Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00683423 | BMS-741672 for Diabetic Neuropathic Pain | PHASE2 | COMPLETED | 50 | — | — | Jul 1, 2008 | Feb 1, 2009 | Oct 12, 2015 | 8 | United States |
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-741672 | DRUG | Tablets, Oral, 100 mg, once daily, 3 weeks |
| Placebo | DRUG | Tablets, Oral, 0 mg, once daily, 3 weeks treatment period, 2 weeks washout, and 2 weeks follow-up |
Inclusion Criteria: * Type 1 or 2 diabetics with painful, distal, symmetrical, sensory-motor neuropathy attributed to diabetes, of at least 12 months duration * Screening HbA1c of ≥ 7% and ≤ 10% * BMI ≤ 40 kg/m2 Exclusion Criteria: * Patients with clinically significant, progressive, or potential...